Comments on SenzaGen Q3 report

SenzaGen has released the Q3 report showing an encouraging and solid performance. We are pleased to see revenue grow by 31% YoY and with OPEX under control. A high rate of recurring sales, increasing cross selling activity and the addition of 31 new customers in 2024 so far holds promise for continued growth. We also note the progress in integrating GARDskin into the ISO standard for the medical device industry which was part of our decision to invest. With a solid cash position, we expect to see break even without additional financing, and we continue to strongly support the concept of animalfree testing.